Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 7/20 | 0.64 |
| ▸ | CSNK1E | P49674 | 3/20 | 0.47 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | CDK9 | P50750 | 1/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.47 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.47 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.47 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.45 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6779673 | 0.86 | MAPK14 (0.62) | MAPK14MAPK13EGFRCSNK1DMAPK12 | |
| SCHEMBL6787411 | 0.85 | MAPK14 (0.61) | MAPK14MAPK13CSNK1DMAPK12MAPK11 | |
| SCHEMBL6610736 | 0.85 | MAPK14 (0.61) | MAPK14CSNK1ECCNA2CDK2CDK5 | |
| SCHEMBL6772274 | 0.84 | MAPK14 (0.60) | MAPK14 | |
| SCHEMBL6601861 | 0.83 | MAPK14 (0.59) | MAPK14MAPK13EGFRCSNK1DMAPK12 | |
| SCHEMBL6775306 | 0.83 | MAPK14 (0.59) | MAPK14MAPK13EGFRCSNK1DMAPK12 | |
| SCHEMBL6780701 | 0.83 | MAPK14 (0.59) | MAPK14CSNK1EMAPK13MAPK12MAPK11 | |
| SCHEMBL6774527 | 0.83 | MAPK14 (0.59) | MAPK14CSNK1ECCNT1CCNA2CDK2 | |
| SCHEMBL6780704 | 0.83 | MAPK14 (0.58) | MAPK14MAPK13CSNK1DMAPK12MAPK11 | |
| SCHEMBL6774285 | 0.83 | MAPK14 (0.58) | MAPK14MAPK13EGFRCSNK1DMAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6787555-B2 | SUCH AS 4-(4-FLUOROPHENYL)-5-(2-PHENYLMETHYLAMINO)PYRIMIDIN-4-YL)-1-ETHOXYMETHYL -(1,2,3)TRIAZOLE FOR INHIBITION OF RELEASE OF INFLAMMATORY INTERLEUKINS; FOR TREATMENT OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, AND CONGESTIVE HEART FAILURE | THE PROCTER & GAMBLE COMPANY | 2004-09-07 | — | — | US | claimed |
| US-20030100558-A1 | Triazole compounds useful in treating diseases associated with unwanted cytokine activity | PROCTER & GAMBLE COMPANY, THE | 2003-05-29 | — | — | US | claimed |
| US-6787555-B2 | SUCH AS 4-(4-FLUOROPHENYL)-5-(2-PHENYLMETHYLAMINO)PYRIMIDIN-4-YL)-1-ETHOXYMETHYL -(1,2,3)TRIAZOLE FOR INHIBITION OF RELEASE OF INFLAMMATORY INTERLEUKINS; FOR TREATMENT OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, AND CONGESTIVE HEART FAILURE | THE PROCTER & GAMBLE COMPANY | 2004-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100558-A1 | Triazole compounds useful in treating diseases associated with unwanted cytokine activity | IL4, IL1A, IL2 | MAPK14 3429/4885CSNK1E 684/4885CCNT1 1769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.